Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Godby

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
American Journal of Hematology|September 25, 2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTHRobert Cornell, Parameswaran Hari, Shijie Tang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
American Journal of Hematology|September 25, 2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTHRobert Cornell, Parameswaran Hari, Shijie Tang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Pageof 16